Skip to Main Content

Rise and shine. Another busy day is on the way. And it appears to be yet another cold one, too. But it is wintertime, after all. To keep warm, yes, we are brewing that mandatory cup of stimulation — we are back to Southern Pecan for those keeping track — and invite you to join us. Once again, we are happy to remind you that a prescription is not required. But now, on with the show. As always, we have assembled a menu of tidbits to get you going. Good luck, today, and do stay in touch. …

Biogen (BIIB) chief executive officer Michel Vounatsos acknowledged Monday that the company was “wrong” to price its Alzheimer’s disease treatment at $56,000 a year, but added that its decision to later slash the cost nearly in half was “courageous,” STAT reports. Speaking virtually at the J.P. Morgan Healthcare Conference, Vounatsos defended the initial price for the drug, known as Aduhelm, as “evidence-based,” and argued “this is a price that eventually we could defend.” But he acknowledged that the widespread negative reaction among physicians, patients, and policymakers proved Biogen was “wrong.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment